title: Evolution of Hematopoietic Cell Transplantation for Immunoglobulin Light Chain Amyloidosis.
abstract: Immunoglobulin light chain amyloidosis is the most common type of systemic amyloidosis. Hematopoietic stem cell transplantation (HCT) is an effective treatment option for AL however due to multi-organ involvement in this disease HCT is feasible in a minority of patients. To maximize the benefit and minimize toxicity it is of paramount importance to optimize the selection of patients for HCT. In this review we discuss evolution of HCT and its typical application to a case of AL amyloidosis.
authors.affiliation: Department of Medicine, Mayo Clinic, Jacksonville, Florida. Electronic address: Sher.taimur@mayo.edu.
authors.forename: Taimur
authors.initials: T
authors.lastname: Sher
authors.affiliation: Department of Medicine, Mayo Clinic, Jacksonville, Florida.
authors.forename: Angela
authors.initials: A
authors.lastname: Dispenzieri
authors.affiliation: Department of Medicine, Mayo Clinic, Jacksonville, Florida.
authors.forename: Morie A
authors.initials: MA
authors.lastname: Gertz
mesh_terms: D000686:Amyloidosis / Q000097:blood / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation / Q000266:history* / Q000379:methods* / Q000639:trends*; D049673:History, 20th Century; D049674:History, 21st Century; D006801:Humans; D007147:Immunoglobulin Light Chains; D008297:Male; D008875:Middle Aged
chemical_list: D007147:Immunoglobulin Light Chains
keywords: AL amyloidosis; Hematopoeitic stem cell transplantation; Immunoglobulin light chain amyloidosis; Stem cell transplantation